Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Related Videos

Related Content

Advertisement

July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

Published: July 26th 2025 | Updated: July 26th 2025

Addressing SDOH in Pediatric Dermatology to Improve Outcomes

Pearl Steinzor

At the Society for Pediatric Dermatology Annual Meeting, Sarah Coates, MD, FAAD, highlights how social drivers shape pediatric skin health and how clinicians can respond.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

July 26th 2025

How to Utilize a Multimodal Treatment Approach for Childhood Obesity

Pearl Steinzor

With obesity rates rising sharply, the American Academy of Pediatrics calls for multimodal strategies to address the crisis in youth.

July 25th 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

Related Content

Advertisement

July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

Published: July 26th 2025 | Updated: July 26th 2025

Addressing SDOH in Pediatric Dermatology to Improve Outcomes

Pearl Steinzor

At the Society for Pediatric Dermatology Annual Meeting, Sarah Coates, MD, FAAD, highlights how social drivers shape pediatric skin health and how clinicians can respond.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

July 26th 2025

How to Utilize a Multimodal Treatment Approach for Childhood Obesity

Pearl Steinzor

With obesity rates rising sharply, the American Academy of Pediatrics calls for multimodal strategies to address the crisis in youth.

July 25th 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.